Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: Escitalopram vs paroxetine

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 605-614

  Boulenger, J P ^a   Hermes, A ^a   Huusom, A K T ^b   Weiller, E ^b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b H LUNDBECK A S   (Denmark)

Author keywords

Comorbid anxiety; Escitalopram; Paroxetine; Remission; Severe major depression

Indexed keywords

ESCITALOPRAM; PAROXETINE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; BACKACHE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; SOMNOLENCE; TREATMENT OUTCOME; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; CITALOPRAM; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; TIME FACTORS;

EID: 76949091626     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903482467     Document Type: Article

References (34)

1. Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract 2004;10:296-306
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627 (Pubitemid 40973437)
3. Boulenger JP, Lavallée YJ. Mixed anxiety and depression: diagnostic issues. J Clin Psychiatry 1993;54(Suppl. 1):3-8
4. Boulenger JP, Fournier M, Rosales D, et al. Mixed anxiety and depression: from theory to practice. J Clin Psychiatry 1997;58(Suppl. 8):27-34
5. Hamilton M. A Rating Scale for Depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
6. Tollefson GD, Holman SL, Sayler ME, et al. Fluoxetine, placebo and tricyclic antidepressants in major depression with and without anxiety features. J Clin Psychiatry 1994;55:50-59
7. Fava M, Rosenbaum JF, Hoog S, et al. Fluoxetine versus sertraline and paroxetine in major depression tolerability and efficacy in anxious depression. J Aff Disorder 2000;59:119-126 (Pubitemid 30317428)
8. Russell JM, Koran IM, Rush AJ, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001;13:18-27
9. Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001;25:131-138
10. Fava M, Rush JA, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus non anxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-351
11. Papakostas GI, McGrath P, Stewart J, et al. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res 2008;161:116-120
12. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
13. Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother 2006;7:429-440
14. Kennedy SH, Andersen HF, Thase M. Escitalopram in the treatment of major depressive disorders: a metaanalysis. Curr Med Res Opin 2009;25:161-175
15. Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006;22:1331-1341
16. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005;20:131-137
17. Bandelow B, Andersen H, Dolberg O. Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety 2007;24:53-61
18. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
19. Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006;67:1428-1434
20. ICH. (1996) ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice. Available from: http://www.emea.europa.eu/pdfs/human/ich/ 013595en.pdf. Accessed 6 September, 2009
21. World Medical Association (WMA). (1964) Declaration of Helsinki: Ethical principles for medical research involving human subjects. Available from: http://www.wma.net/e/ethicsunit/helsinki.htm. Accessed 6 September, 2009
22. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl. 1986;326:1-37
23. Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD, National Institute of Mental Health
24. Fava M, Rush J, Alpert JE, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J. Psychiatry 2006;51:823-835
25. Nelson JC. Anxious depression and response to treatment. Am J Psychiatry 2008;165:297-299
26. World Health Organisation (WHO). The ICD-10 Classification of Mental Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: WHO; 1992
27. Thase ME. Treatment of severe depression. J Clin Psychiatry 2000; 61(Suppl 1):17-25
28. Kasper S, Baldwin DS, Larsson Lönn S, et al. Superiority of escitalopram to paroxetine in the treatment of depression. Eur Neuropsychopharmacol 2009;19:229-239
29. Kasper S, Sacher J, Klein N, et al. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 2009;24:119-125
30. Papakostas GI, Petersen T, Hughes M, et al. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorders. Psychiatry Res 2004;126:287-290
31. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple treatments meta-analysis. Lancet 2009;373:746-758
32. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-932
33. TLV (The Dental and Pharmaceuticals Benefits Agency). The review of antidepressants. December, 2008. Available online at http://www.tlv.se/Upload/ Genomgangen/review-antidepressants.pdf. Accessed 29 October, 2009
34. Wade AG, Ferná ndez JL, Francois C, et al. Escitalopram and duloxetine in Major Depressive Disorder. A pharmacoeconomic comparison using UK cost data. Pharmacoeconomics 2008;26:969-981